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Abstract Seventy per cent of breast cancers are luminal carcinomas that express estrogen receptor alpha (ER). 
 For several decades, its expression has been used as a therapeutic target in patients with breast 
cancer. These therapies are aimed at blocking ER or inhibiting ligand synthesis. The expression of progester-
one receptors (PR) is evaluated as a prognostic factor together with ER. It has been shown that there are two 
predominant PR isoforms with different molecular weight, isoform A and isoform B, which are not distinguished 
by immunohistochemical techniques. The available evidence indicates that the PR isoform ratio may have both a 
prognostic and predictive value of the response to antiprogestin treatment. In luminal mammary carcinomas, androgen 
receptors (AR) are expressed in a high percentage and the AR/ER or AR/PR ratio could be a prognostic factor. In 
ER negative (-) tumors, AR expression is an indicator of poor prognosis and it is proposed that they may be sus-
ceptible to antiandrogen treatment. Finally, the expression of glucocorticoid receptors (GR) would be an indicator 
of good or bad prognosis in luminal or ER- tumors, respectively. In ER- tumors, metastases express higher levels 
of nuclear GR than primary tumors and therapies that block GR could improve the efficacy of chemotherapy. Given 
the crosstalk of pathways triggered by different hormone receptors, it is possible that in the future, a therapeutic 
scheme can be administered that contemplates the expression of ER, PR isoforms, AR and GR.
 Key words: breast cancer, estrogen receptors, progesterone receptor isoforms, androgen receptors, glucocorticoid 
receptors
Resumen Receptores hormonales en cáncer de mama: receptores de estrógenos y algo más. El 70
 por ciento de los carcinomas mamarios son luminales y expresan receptores de estrógenos alfa 
(RE). Desde hace varias décadas, su expresión se utiliza como blanco terapéutico en pacientes con cáncer 
de mama. Estas terapias están dirigidas a bloquear el RE o a inhibir la síntesis del ligando. La expresión de 
receptores de progesterona (RP) se evalúa como factor pronóstico junto con los RE. Se ha comprobado que 
existen dos isoformas predominantes de RP de distinto peso molecular, isoforma A e isoforma B, que no se 
distinguen por técnicas de inmunohistoquímica. Las evidencias indican que la proporción de isoformas de RP 
podría tener tanto un valor pronóstico como predictivo de la respuesta a un tratamiento con antiprogestágenos. 
En tumores mamarios luminales, los receptores de andrógenos (RA) se expresan en un alto porcentaje y la 
proporción de RA/RE o RA/RP podría ser un factor pronóstico. En tumores RE-, la expresión de RA es indica-
dor de mal pronóstico y se propone que serían susceptibles a un tratamiento con antiandrógenos. Por último, 
la expresión de receptores de glucocorticoides (RG) sería un indicador de buen o mal pronóstico en tumores 
luminales o RE-, respectivamente. En tumores RE-, las metástasis expresan mayores niveles de RG nuclear 
que los tumores primarios y las terapias que bloquean los RG podrían mejorar la eficacia de la quimioterapia. 
Dado los entrecruzamientos de vías gatilladas por distintos receptores hormonales es posible que en un futuro 
se pueda administrar un esquema terapéutico que contemple la expresión de RE, isoformas de RP, RA y RG.
 Palabras clave: cáncer de mama, receptores de estrógenos, isoformas de receptor de progesterona, receptor 
de andrógenos, receptor de glucocorticoides
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Statistics indicate that one out of eight women will 
develop breast cancer throughout their lives. From the 
clinical point of view, it is essential to know the age, 
personal and family history of breast and ovarian cancer, 
as well as the tumor size, the presence of axillary lymph 
nodes and the time elapsed from the first symptom to the 
consultation. Once the biopsy or surgery is performed, 
a histopathological examination is carried out to classify 
the tumor type and establish the histological grade. These 
characteristics, together with the biomarkers measured by 
immunohistochemistry (IHC), provide the diagnosis and 
constitute prognostic and predictive values of therapeutic 
response. Once the tumor is categorized and the patient 
is staged, it is possible to evaluate the risk of relapse in 
order to make the appropriate therapeutic decisions in 
each case.
The biomarkers that are currently used include the 
determination of estrogen receptor alpha (ER) and proges-
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terone receptors (PR), overexpression of the epidermal 
growth factor receptor type 2 (HER2 or c-erb-B2) and the 
expression level of the cell proliferation marker, Ki-67. 
These biomarkers are evaluated by IHC and, when the 
result of HER2 is doubtful, gene amplification is verified 
by in situ hybridization techniques. In the case of hormone 
receptor positive tumors with moderate Ki-67 index, where 
it is difficult to determine the benefit of chemotherapy, 
molecular platforms are used. These platforms report 
high or low risk scores that collaborate with oncologists in 
making decisions. Currently, the most used and accepted 
genomic test in Argentina is the Oncotype DX. This assay 
measures the expression of 21 genes by gene amplifica-
tion (RT-PCR). The expression of 16 oncogenes and 5 
reference genes is evaluated and a score assigned to the 
result that informs about the risk of disease recurrence. If 
the score is less than 26, the risk of recurrence would be 
low and, therefore, the administration of chemotherapy 
is not advised. On the other hand, if the score obtained 
is greater than or equal to 26, chemotherapy is recom-
mended. For premenopausal patients, there is a range of 
uncertainty for samples with a score between 18 and 30 
(breastcancer.org).
Most (70-75%) breast carcinomas express ER and 
PR and, according to the molecular classification, these 
tumors correspond to the luminal type. In turn, these 
tumors are subclassified in luminal A (Lum A) or B (Lum 
B) according to whether they have a low or high rate of 
proliferation, respectively1. The latter, in addition to ex-
pressing ER, usually express lower PR levels compared 
with Lum A tumors and may also express HER2. ER+/
PR- breast carcinomas are also included in this group 
(Table 1). From the clinical point of view, they arouse 
special interest, since they have a worse prognosis than 
ER+/PR+ tumors. It is postulated that these tumors have 
exacerbated growth factor signaling pathways and spe-
cific mutations associated with this phenotype have been 
described2. Luminal tumors have a better prognosis than 
the rest of breast carcinomas and they can respond to 
endocrine therapies aimed at blocking ER (tamoxifen or 
fulvestrant) or, at inhibiting the endogenous production of 
their natural ligands (aromatase inhibitors). The group of 
tumors that do not express ER, is formed by a subgroup 
that overexpresses HER2, and therefore is susceptible to 
a therapy with antibodies directed to block this receptor, 
or by tumors called triple negative (TN) since they do not 
TABLE 1.– Frequency of mammary carcinomas according to the expression of hormonal receptors and
HER2 and their corresponding molecular classification
ER % Tumor subtype based %* %* %** Molecular 
  on PR and HER2    classification**
  expression 
ER+ 73.5 ER+PR+ 66.6   
  ER+PR+HER2-  89 59.3 Lum A (Ki-67< 14) or 
      Lum B (Ki-67 ≥ 14)
  ER+PR+HER2+  11 7.3 Lum B
  ER+PR- 6.9   
  ER+PR-HER2-  65.5 4.5 Lum B
  ER+PR-HER2+  34.5 2.4 Lum B
ER- 26.5 ER-PR+ 1.3   
  ER-PR+HER2-  65.5 0.9 Similar to TN
  ER-PR+HER2+  34.5 0.4 Similar to TN o Her2 +
  ER-PR- 25.2   
  ER-PR-HER2-  61.2 15.4 TN: basal-like immune 
      associated (BLIA),
      basal-like immune
      suppressed (BLIS),
      luminal androgen
      receptor (LAR) and,
      mesenquimal-like
      (MES)
  ER-PR-HER2+  38.8 9.8 HER2
*Percentages obtained from Bae et al, BMC Cancer 2015; 15: 1138
**Molecular classification of Perou, Sorlie et al, Nature 2000; 406: 747-52; Burstein et al, Clin Cancer Res 2015; 21: 1688-98.
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express ER, PR or HER2. According to the molecular 
classification, TN tumors include basal tumors. These 
tumors have the worst prognosis1 (Table 1) and do not 
yet have a standardized targeted therapy. On the other 
hand, there is a controversy regarding ER-/PR+ tumors. 
This group accounts for less than 2% of breast cancers 
and the controversy relies in the fact that some research-
ers consider them as an independent group with their 
own characteristics, while others consider that diagnostic 
errors, either by PR over-valuation or ER sub-valuation, 
led to their classification, since when several cases were 
reviewed, many of them changed their category3. Likewise, 
the study of this group determined that the cell proliferation 
rate, the percentage of P53 mutations and overall patient 
survival resemble TN tumors more than luminal tumors4.
Hormone receptors
ER, PR, androgen (AR), mineralocorticoid, glucocorticoid 
(GR), retinoic acid, and other less-known receptors belong 
to the steroid receptor superfamily. They share a similar 
structure that include hormone binding, nuclear translo-
cation, DNA binding and transactivation domains. These 
receptors are activated after high affinity hormone binding 
and, once active, they behave as transcription factors by 
binding to the promoters of target genes at specific binding 
sites. Alternatively, they can be activated in the absence 
of ligand since they can be phosphorylated by kinases 
such as MAPK and AKT, which are usually overactivated 
in neoplastic processes. The activated receptors can in 
turn act as coactivators, potentiating the effects of other 
transcription factors. In recent years, it has been shown 
that the different receptors can interact with each other in 
the promoters of the target genes, showing a higher level 
of complexity in the regulation of biological responses5-8. 
Unraveling the mechanism of action of steroid hormones 
has been of great help to understand the mechanisms 
related to endocrine resistance.
Considering that endocrine therapies are much less in-
vasive than nonspecific therapies such as chemotherapy, 
it is extremely important to determine the mechanisms 
underlying hormone-regulated tumor growth and, whether 
blocking other hormone receptors, different from ER, could 
be an additional therapeutic alternative to improve the 
effects of current endocrine therapies.
Estrogen receptors
Elwood Jensen (1920-2012) can be considered as the fa-
ther of hormone receptors, especially ER. Then, J. Gorski 
and G. Greene made great contributions demonstrating 
that these receptors had a predominant nuclear location 
(reviewed in9). Currently, the presence of ER in breast 
carcinomas is determined by IHC. These are considered 
ER+ if the staining is located in the cell nucleus while 
cytoplasmic staining is ignored. However, more than 
thirty years ago, receptors were evaluated by binding 
techniques, that consisted in measuring the ability of the 
receptors to bind radioactive hormone with high affinity in 
a cell extract. At that time, this method did not distinguish if 
more than one type of receptor bound to the hormone or, 
if different cell populations bound estradiol with the same 
affinity. Subsequently, in the nineties, Jan-Åke Gustaffson 
discovered a different estrogen receptor that binds estro-
gens with high affinity. This novel receptor was named ER 
beta to differentiate it from the already known ER alpha10. 
While these two isoforms are encoded by genes located 
on different chromosomes, they share a high sequence 
homology. The role of ER beta in breast cancer is not 
clear and it is not evaluated in the clinic.
The antibodies that are used in diagnostic pathology 
specifically assess expression of ER alpha. However, its 
detection by IHC cannot distinguish whether the receptor 
is functional, mutated, or if it is a lower molecular weight 
isoform that maintains the epitope recognized by the 
antibody.
As we mentioned in previous paragraphs, ER determi-
nation is important not only because it is an independent 
prognostic marker, but also because it is a predictive 
marker of response to treatment. Patients with breast 
tumors with ER expression levels greater than or equal 
to 1% can be treated with endocrine therapy. However, 
in a patient with a tumor with 99% of ER- cells, a worse 
response to treatment is expected compared to those 
tumors in which all their cells express ER.
For a long time, Fuqua et al. have postulated that one of 
the mechanisms that explain endocrine therapy resistance 
is the presence of mutated ERs11. At the time, no correla-
tion was found between the presence of these mutations 
and the response to treatment, and this theory was not 
sustained. Interestingly, in the last few years this concept 
has resurfaced since metastases in many patients express 
mutated ER that were not present in the original tumor12.
Progesterone receptors
Why are PRs evaluated if, until now, there is no treat-
ment aimed at blocking them? What is the benefit of their 
quantification? It has been shown that, in ER+ mammary 
carcinomas, PR quantification has prognostic value. As 
previously mentioned, the ER+/PR- subgroup is of worse 
prognosis, either because it is a different entity or because 
it implies that ERs are not functional since one of the 
physiological effects of ER is to induce PR synthesis. In 
the same way as for ERs, they were formerly evaluated by 
ligand binding techniques and they are currently measured 
by IHC. The PR gene codes for at least two major proteins, 
isoform B (PRB) of higher molecular weight and isoform 
A (PRA) which is a truncated protein that lacks the first 
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161 amino acids. Since PRA is included within PRB, it is 
very difficult to have antibodies that exclusively recognize 
PRA. There are few studies in which the expression of 
both isoforms has been quantified (reviewed in 13). The 
consensus is that in the normal mammary gland the same 
level of either PR isoform is expressed, whereas this ratio 
is altered in tumors, where PRA often predominates over 
PRB. Some authors propose that tumors with a higher 
proportion of PRA than PRB would have a lower response 
to tamoxifen and, therefore, worse prognosis (reviewed in 
13). On the contrary, in our laboratory we have shown that 
tumors with a higher proportion of PRA than PRB share 
characteristics with Lum A tumors and, consequently, 
they would have a better prognosis than those with the 
opposite proportion, which are similar to Lum B. Moreover, 
the latter are tumors with a higher cell proliferation rate 
and lower total PR expression14. Likewise, the results of 
our laboratory show that tumors with higher levels of PRA 
than PRB respond ex vivo to treatment with antiprogestins 
such as mifepristone14. These studies suggest that PR 
could also be used as a therapeutic target to be used in 
conjunction with current endocrine therapy in patients 
selected according to their PR isoform profile.
On the other hand, it should be noted that progestins 
have been used in high concentrations in the eighties and 
other authors have proposed their use in combination 
with conventional endocrine therapy. Currently, there are 
several ongoing studies in the clinic testing the progestin 
megestrol acetate in patients with advanced breast cancer. 
The challenge in this field is to distinguish which patients 
would benefit from either treatment.
Androgen receptors
ARs are not routinely measured in breast cancer patients. 
Two isoforms and several alternative splicing variants, 
encoded by the same gene, have been described. The 
most commonly observed variant is the one with the high-
est molecular weight, which is expressed in approximately 
60-70% of mammary carcinomas15. Considering that 
an interrelation between ER and AR has been demon-
strated16, determining AR expression was attractive not 
only to explore AR as an additional therapeutic target, but 
also as a prognostic biomarker in breast cancer. In fact, 
recent studies have determined that the ratio AR/ER > 2 
is associated with a worse response to treatment with 
tamoxifen and a worse disease-free survival, so that the 
measurement of this relationship could have prognostic 
value.
The current consensus is that it is a marker of good 
prognosis in luminal tumors and a worse prognosis 
marker in TN breast cancer17 (Table 2). This subgroup of 
TN tumors expressing AR has been cataloged as a LAR 
subtype (Luminal Androgen Receptor), and it has been 
observed that these patients have a lower disease-free 
survival in response to conventional treatments. However, 
the expression of AR in these tumors could make them 
susceptible to antiandrogen treatment.
In 1988, flutamide was the first AR antagonist tested in 
patients with breast cancer, but it did not prosper, prob-
ably due to its side effects and lack of clear response. 
Years later, interest was rekindled with AR determination 
in breast cancer and the development of new drugs for 
prostate cancer treatment. In trials with bicalutamide, 
better responses were obtained in patients selected 
for having more than 10% AR and, currently, there are 
several studies that use third generation AR antagonists, 
such as enzalutamide, and other AR modulators, such 
as enobosarm, in combination with aromatase inhibitors.
Glucocorticoid receptors
The GRs are encoded by the NR3C1 gene. This gene 
codes for several isoforms with different cell localization 
and distinct biological functions. Like ARs, GRs are not 
currently evaluated in breast carcinomas; however, nu-
merous studies suggest that using these receptors as a 
therapeutic target may have certain benefits.
In a retrospective meta-analysis study with more than 
1000 ER+ patients in early stages, it was observed that 
high GR mRNA levels were associated with a better prog-
nosis compared to patients with low or no GR expression. 
However, the opposite was observed when evaluating 
300 ER- patients in whom GR expression was associ-
ated with a worse prognosis18 (Table 2). These results 
are very similar to those reported for AR. Likewise, it was 
demonstrated that there is a cooperation between ER and 
GR so that when both receptors are activated there is a 
greater positioning of these receptors in genes related to 
cell differentiation19. Given that GR expression was as-
sociated with survival and chemoresistance genes in TN 
tumors, one study suggests treatment with GR antago-
nists together with chemotherapy in order to improve the 
therapeutic effect20.
In conclusion, given the interplay between different 
steroid receptor signaling pathways, it is extremely impor-
tant to evaluate their role both in luminal and TN tumors 
since, in the absence of ER, the AR and GR could have 
opposite functions. We can envisage that in the future, 
the determination of PR isoforms, as well as the determi-
nation of AR and GR, will allow us to classify tumors as 
quadruple or quintuple positive or negative, adding other 
prognostic and/or predictive factors for treatments with 
endocrine agonists/antagonists.
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TABLE 2.– AR and GR in mammary carcinomas with or without ER and PR expression 
Hormone Experimental data  Clinical data 
receptors
ER+PR+
 AR+1 In vitro 
  • Androgens: ↓ cell proliferation at • > disease free survival and overall
   low concentrations and ↑ at high  survival, especially in Lum A
   concentrations • AR/ER ≥ 2.0 higher risk to failure to
  • AR antagonists: ↓ cell  tamoxifen therapy. A similar trend is
   proliferation  seen with AR/PR
  In vivo
  • Androgens and AR antagonists: ↓
   tumor growth 
 GR+2 In vitro  • > GR: ↑ overall survival
  • Dexa* (1 μM): ↓ cell proliferation
   and cell migration in MCF-7 cells
  In vivo
  • Dexa (0.1 mg/kg; ip, 2x/week): ↓
   tumor growth (MCF-7) 
ER-PR-
 AR+1 In vitro • HER2+: unclear role of AR
  • Androgens: ↑ cell proliferation. ↑ • TN: Some studies report better and
   HER2 mRNA. HER2 blockage ↓  others worse overall survival
   androgen response 
  • AR antagonists: ↓ cell
   proliferation
  In vivo  
  • Androgens: ↑ tumor growth 
  • AR antagonists: ↓ tumor growth   
 GR+2 In vitro  • Metastasis: > GR nuclear localization
  • Dexa: ↓ cell proliferation and cell • GR antagonists: improve the effect of
   migration in MDA-MB-231 cells  chemotherapy
  In vivo • > GR: ↓ overall survival 
  • Dexa: ↓  tumor growth
  • Metastasis: ↑ GR nuclear
   localization 
*Dexa: dexamethasone, glucocorticoid agonist
1Venema et al, Pharmacol Therap 2019, in press; 2Kumar et al, Carcinogenesis 2019; 40: 335-48
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Para el investigador básico, relatar sus experimentos no resulta tarea sencilla. Suele 
sumergirse en ellos, en la “torre de marfil”, aislado de la realidad cotidiana acompañado por 
la ahora infaltable computadora. Por lo general, el lego piensa que se trata de un varón, un 
excéntrico distraído, nunca una mujer. Pero hubo mujeres científicas, de a cuenta gota en 
los tiempos lejanos, hasta que poco a poco penetraron en “el mundo del investigador” –como 
me gusta denominarlo– y hoy ya se destacan cada vez más. 
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